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Abstract 
P-glycoprotein (P-gp), an active efflux pump of antitumor drugs, is strongly expressed in endothelial cells of the blood brain barrier 
(BBB). Two proteins (155 and 190 kDa) were detected by Western blot analysis of beef and rat capillaries with the monoclonal antibody 
(MAb) C219. In order to characterize the nature of these proteins, their profile of solubilization by different detergents was established 
and compared with that of P-gp from the CHRC5 tumoral cell line. The 155 kDa protein (p155) of capillaries and the P-gp of CHRC5 
cells were well solubilized by deoxycholate and Elugent, whereas the 190 kDa protein (p190) was only solubilized by sodium 
dodecylsulfate (SDS). Both proteins have different patterns of extraction by Triton X-114, p155 partitioning as a membrane protein, while 
p190 was insoluble. Deglycosylation of capillary proteins resulted in a 27-28 kDa decrease in the apparent molecular weight of p155, 
similar to that observed for the P-gp of CHRC5 cells, but a decrease of only 7-8 for p190. Only p155 was immunoprecipitated by MAb 
C219. These results suggest hat only p155 is the P-gp in BBB and that MAb C219 cross-reacts with a 190 kDa MDR-unrelated 
glycosylated protein. Consequently, the use of this antibody, which is frequently used to detect P-gp in tumors, could be a pitfall of 
immunohistochemistry screening for cancer tissues and lead to false positive in the diagnosis of MDR. 
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1. Introduction 
Multidrug resistance (MDR) constitutes a major obsta- 
cle in the clinical treatment of cancer [1]. The overexpres- 
sion of a membrane glycoprotein of 150-170 kDa [2-4], 
P-glycoprotein (P-gp), is considered to be the cause of this 
resistance to multiple chemotherapeutic drugs [5]. P-gp has 
been cloned from different species including mouse and 
hamster [6] which possess three gene classes (I, II and III) 
and from human who has two classes (I and III) [5,7,8]. A 
model based on its amino acid sequence suggests that P-gp 
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is an integral membrane protein with 12 transmembrane 
domains. Hydrophilic domains include an external glyco- 
sylation site and two internal ATP-binding sites [5,9]. 
The presence of P-gp has been demonstrated in normal 
tissues uch as adrenal medulla, liver, kidney, colon [10,11] 
and endothelial cells of brain capillaries [11-13] where it 
is strongly expressed. Brain capillaries have a unique 
structure and constitute a selective barrier between blood 
and brain [14-16]. A recent report showed that P-gp has a 
pharmacological effect in brain, it limits the amount of 
drug accumulating [17]. Viable mice with a disruption of 
the mdrla P-glycoprotein gene have been generated. These 
chimeric mice presented extreme sensitivity to ivermectin, 
which was associated with high accumulation of iver- 
mectin in the brain. The absence of mdrla P-gp increased 
the accumulation of vinblastine in the brain, where it was 
eliminated much more slowly [17]. 
Among the various antibodies available to detect P-gp 
in human tumors and in animal studies, MAb C219 is by 
far the most widely used. MAb C219 recognizes the 
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epitope VQEALD, which is a conserved carboxy-terminal 
cytoplasmic sequence. The extensive use of this antibody 
is justified by its high affinity for the different classes of 
P-gp isoforms identified so far in most species where it 
was studied, including human, rat, mouse, beef, hamster 
and cell lines of various origins [2,18]. However, cross-re- 
activity of MAb C219 have already been reported with a 
protein of 65 kDa by Western blot and with a muscular 
protein by immunohistochemistry [19,20]. In this paper, we 
present a biochemical characterization f P-gp in purified 
BBB endothelial cells. A tumoral cell line from chinese 
hamster ovaries (CHRC5) which expresses the MDR phe- 
notype was used as a reference [7,9,21]. Two proteins were 
immunodetected with MAb C219 in beef and rat brain 
capillaries. Different physico-chemical treatments were 
performed to compare these two proteins and determine 
whether they are related to P-gp. Our results suggest that 
p155 is P-gp while p190 is MDR-unrelated. 
2. Materials and methods 
2.1. Chemicals 
Dextran T-70 and protein A sepharose 4 fast flow were 
purchased from Pharmacia LKB Biotechnology (Montr6al, 
Quebec). Electrophoresis reagents were from Bio-Rad 
(Mississauga, Ontario). MAb C219 was a product of ID 
Labs (London, Ontario). Horseradish peroxidase-con- 
jugated rabbit anti-mouse IgG and enhanced chemilumi- 
nescence reagents were obtained from Amersham (Oak- 
ville, Ontario). Endoglycosidase F/N-glycosidase F and 
Hepes were from Boehringer-Mannheim (Laval, Quebec). 
Zwittergent 3-14, Hecameg and Elugent were products of 
Calbiochem (La Jolla, CA), Triton X-100 and X-114 and 
Tween 20 were from Bio-Rad and SDS was from Pierce 
(Rockford, IL). All the other eagents were purchased from 
Sigma (St. Louis, MO). 
2.2. Purification of brain capillaries 
Fresh bovine brains were obtained from a local abattoir 
and transported to the laboratory in ice-cold physiological 
buffer (PB) composed of 147 mM NaC1, 4 mM KC1, 3 
mM CaCI 2, 1.2 mM MgCI 2, 5 mM glucose and 15 mM 
Hepes/Tris, pH 7.4. Beef brain capillaries were then 
purified with the procedure of Dallaire et al. [22]. Brain 
capillaries were also isolated from Sprague-Dawley rats. 
For both species, the pia mater was removed, and the 
cerebral cortex was homogenized in 5 volumes of PB with 
a polytron (Brinkman Instruments, Rexdale, Ontario). The 
homogenates were mixed with an equal volume of 26 or 
31% (w/v) Dextran T-70 in PB for bovine and rat cortex, 
respectively. The final pellets were resuspended in PB and 
stored at - 180°C. 
2.3. Isolation of membranes from CHRC5 cells 
The CHRC5 cells were resuspended in homogenate 
medium (HM) composed of 50 mM mannitol and 5 mM 
Hepes/Tris, pH 7.5, homogenized 1 min with a polytron 
and centrifuged at 30 000 X g for 20 min at 4°C. The final 
pellets were resuspended in MH and stored at -80°C. 
2.4. Immunodetection f P-gp 
P-gp was detected by Western blot analysis using MAb 
C219. SDS-polyacrylamide gel electrophoresis (SDS- 
PAGE) was performed with a Mini-Protean II apparatus 
(Bio-Rad) according to the method of Laemmli [23]. Brain 
capillaries or CHRC5 membrane preparations were resus- 
pended in sample buffer composed of 62.5 mM Tris/HCl 
pH 6.8, 10% glycerol, 2% SDS, 5% fl-mercaptoethanol 
and 0.00625% bromophenol b ue to a final protein concen- 
tration of 0.5 mg/ml. The samples were agitated 30 min at 
25°C or heated 3 min at 85°C and loaded on 6.25% 
acrylamide/bisacrylamide (29.1:0.9) gels. Electrophoresis 
was carried out at a constant voltage of 120 V. Proteins 
were transferred electrophoretically to a 0.45/~m pore size 
polyvinylidene difluoride (PVDF) membrane using a Milli- 
Blot Graphite Electroblotter I apparatus (Millipore, Bed- 
ford, MA). The transfer buffer contained 96 mM glycine, 
10 mM Tris and 10% methanol. The transfer was carried 
out for 1 h at a constant amperage of 1 mA/cm 2. Hy- 
drophobic or non-specific sites were blocked overnight at 
4°C with 5% powdered skimmed milk in Tris-buffered 
saline (50 mM Tris and 150 mM NaC1) containing 0.3% 
Tween 20 (TBS-T). Membranes were washed three times 
for 15 min in TBS-T. The PVDF membranes were incu- 
bated with MAb C219 (200 ng/ml) in TBS-T, 1% bovine 
serum albumin (BSA) and 0.05% NaN 3 for 2 h at 37°C. 
Membranes were washed four times for 15 min and incu- 
bated 1 h at room temperature with horseradish peroxi- 
dase-conjugated rabbit anti-mouse IgG (1:2000) in TBS-T 
containing 2% milk powder. PVDF membranes were 
washed four times for 10 min in TBS-T, P-gp was detected 
using chemiluminescence r agents (ECL). Molecular 
weights were determined with a calibration curve made 
with Bio-Rad standards: myosin (200 kDa), /3-galacto- 
sidase (116 kDa), phosphorylase b (97 kDa), bovine serum 
albumine (66 kDa) and ovalbumine (45 kDa). 
2.5. Triton X-I14 phase partitioning 
Brain capillary proteins (5 mg/ml) were solubilized at 
4°C for 30 min in PB containing 2% Triton X-114. The 
mixture was centrifuged at 100000 X g for 30 min at 4°C 
and the pellet was resuspended in PB and 1% SDS. The 
supernatant was layered over a cushion composed of 1:10 
volume of 250 mM sucrose and incubated for 10 min at 
30°C. The phase separation was completed by centrifuging 
the turbid mixture at 2000 X g 5 min at 30°C. The upper 
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detergent-poor phase was separated from the lower deter- 
gent-rich phase with a pasteur pipette. 
2.6. Deglycosylation 
Capillaries and crude membranes from CHRC5 cells 
were resuspended in HM at a protein concentration of 6 
mg/ml. Proteins were solubilized 10 min at 25°C in 0.5% 
SDS. The samples were diluted in HM containing 0.25% 
fl-mercaptoethanol, 1% Triton X-100, 2 U/mg protein of 
endoglycosidase F/N-glycosidase F and proteinase in- 
hibitors (2 /.tg/ml aprotinin, 10 /zg/ml pepstatin A and 
100 /xg/ml bacitracin). Deglycosylation was carried out 
overnight at 25°C. Laemmli's sample buffer was added 
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2.7. Peptide synthesis 
The peptide VQEALD was synthesized with an Applied 
Biosystems ynthesizer model 431A (Mississauga, On- 
tario) using Fmoc (9-fluoronylmethyloxycarbonyl) chem- 
istry. Peptide purity was verified with a semipreparative 
HPLC column. 
Fig. 2. Solubilization of P-gp from brain capillaries. Brain capillary 
proteins (0.5 mg/ml)  from rat were solubilized 30 min at 25°C in 
homogenate medium with the following detergents: 0.4% deoxycholate 
(D), 0.1% Zwittergent 3-14 (Z), 1.2% CHAPS (C), 1.4% n-octyl- 
glucoside (O), 1.3% Hecameg (H) and 1.5% Elugent (E). Proteins (10 
/zg) from supernatants (S), pellets (P) and untreated capillaries (Cap) 
were resolved by SDS-PAGE and detected by Western blot analysis. 
2.8. Immunoprecipitation 
Brain capillaries and membranes from CHRC5 cells 
were washed and resuspended in TBS (pH 7.6) at a protein 
concentration f 1 mg/ml. SDS (0.5%) was added and the 
solubilization was carried out for 30 min at 25°C. Samples 
were diluted (1:5) in TBS containing 1.25% Triton X-100, 
0.625% deoxycholate and proteinase inhibitors, and cen- 
trifuged at 14000 X g for 10 min. MAb C219 (3 /zg/ml) 
was added to the supernatants, and samples were incubated 
overnight at 4°C. Protein A sepharose quilibrated in TBS 
containing 1% Triton X-100, 0.5% deoxycholate and 0.1% 
SDS (RIPA) was added (120 /zl/ml). The suspensions 
were incubated for 1 h at 25°C and centrifuged at 8000 x g 
for 4 min. Pellets were washed once with RIPA buffer, 
Heated  -!- -I- - -  
B R B R 
kDa 
- -  200  
- -116  
i 97 
Fig. l. Detection of P-gp from brain capillaries. Proteins (10 /.tg) from 
beef (B) and rat (R) were heated 3 min or solubilized 30 min at room 
temperature before SDS-PAGE. Proteins were transferred onto PVDF 
membranes and analyzed by Western blot with MAb C219 as described 
in Materials and methods. 
once with RIPA diluted 1:10 in TBS and twice with TBS. 
Sample buffer was added to the pellet for SDS-PAGE and 
Western blot analysis as described above. 
3. Results 
Two proteins with apparent molecular mass of 155 and 
190 kDa from beef and rat brain capillaries were immun- 
odetected with the MAb C219. The detection of p155 was 
significantly reduced by heating the samples from both 
species (Fig. 1). However, p190 was always present with 
the same intensity, whether the samples were heated or not 
before electrophoresis. 
The two proteins revealed by MAb C219 possess differ- 
ent patterns of solubilization by various detergents. At 
twice their critical micellar concentrations (CMC), several 
detergents solubilized very well p155 from brain capillar- 
ies (Fig. 2). Deoxycholate, an anionic detergent, and elu- 
gent, a mixture of non-ionic detergents, were the most 
effective in solubilizing p155 (Fig. 2). These detergents 
also efficiently solubilized P-gp from CHRC5 cells (Table 
1). In contrast, p190 was extracted only by SDS (Table 1) 
and by urea (results not shown). 
Triton X-114 phase partitioning is a method used to 
separate the proteins according to their solubilization by 
this detergent [24] and it allows to evaluate the degree of 
hydrophobicity of proteins [25]. Fractionation of beef and 
rats brain capillary proteins with Triton X-114 showed that 
the two proteins detected by MAb C219 partitioned in 
different phases (Fig. 3). P155 was extracted by Triton 
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Table 1 
Solubilization of P-gp from the membrane ofCHRC5 cells and proteins 
from brain capillaries detected with MAb C219 
Detergent (concentration) % Solubilization 
P-gp from CHRC5 cells p155 p190 
SDS (0.5%) 95 80 48 
Hecameg (1.3%) 84 31 0 
Octylglucoside (1.4%) 82 15 0 
Elugent (1.5%) 81 90 0 
Zwittergent 3-14 (0.1%) 81 34 0 
Deoxycholate (0.4%) 78 88 0 
CHAPS (1.2%) 75 30 0 
Proteins from rat brain capillaries (1 mg/ml) and CHRC5 cells were 
solubilized with different detergents 60 min at 25°C and immunodetected 
with MAb C219 as described in Materials and methods. Autoradiograms 
were scanned with an LKB Ultroscan XL enhanced laser densitometer 
and the relative area under each peak was calculated. Data shown 
represent the percentage of solubilization compared tO the control. 
X-114 and partitioned in the detergent-rich phase, while 
p190 was completely insoluble in Triton X-114 and re- 
mained in the first pellet. The fractionation profile of p155 
and p190 was identical for beef and rat capillaries. 
Both brain capillary proteins detected with MAb C219 
are glycoproteins since both proteins had a different profile 
of migration after endoglycosidase F/N-g lycos idase-F  
treatment (Fig. 4). The difference in migration rate is 
greater for p155 (27-28 kDa) than for p190 (7 -8  kDa). 
The shift in the apparent molecular weight of p155 from 
capillaries was similar to that obtained for the P-gp of 
CHRC5 cells after the same deglycosylation treatment. 
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Fig. 3. Phase partitioning of brain capillary proteins with Triton X-l14. 
Brain capillary proteins (lane 1) from beef (A) and rats (B) were 
solubilized in 2% (w/v) Triton X-114. After a 30 min centrifugation at 
lO0000X g, these were separated into pellet (lane 2) and supernatant 
(lane 3) fractions. Phase separation of the latter gave a detergent-poor 
(lane 4) and a detergent-rich p ase (lane 5). The proteins from each 
fraction were separated by SDS-PAGE and detected by Western blot 
analysis. 
RAT CHRC5 





Fig. 4. Deglycosylation f brain capillary and CHIC5 membrane pro- 
teins. Solubilized proteins from rat (RAT) and CHRC5 crude membranes 
(cHRc5) were incubated with (+) and without ( - )  endoglycosidase 
F/N-glycosidase F as described in Materials and methods. Electrophore- 
sis and immunodetection with MAb C219 were described as mentioned 
previously. Untreated capillary or CHaC5 cells are also shown (C). 
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Fig. 5. Inhibition of MAb C219 binding by peptide VQEALD. Western 
blot analysis of the rat brain capillary proteins p155 (A), p190 (O) and 
CHRC5 membranes (11) were performed as described in Materials and 
methods with the addition of peptide to the primary antibody incubation 
medium. Autoradiograms were scanned with an LKB Ultroscan XL 
enhanced laser densitometer and the relative area under each peak was 
calculated. Data shown represent the percentage of solubilization com- 
pared to the control. 
Competition studies with the VQEALD peptide have 
shown that the detection, with MAb C219, of p155 and 
P-gp from CHRC5 cells is displaced at a lower peptide 
concentration than that of p190 kDa (Fig. 5). The binding 
of MAb C219 to the P-gp of CHRC5 cells and to p155 is 
completely inhibited by 10 mM peptide. At the same 
peptide concentration, however, binding of MAb C219 to 
p190 was inhibited only by 45%. 
Immunoprecipitation f  brain capillary proteins with 
MAb C219 revealed that only p155, but not p190, is 
immunoprecipitated (Fig. 6). 
4. Discussion 
Two proteins bands of comparable intensity were de- 
tected by Western blot analysis of brain capillaries using 
MAb C219. The physicochemical characteristics of these 
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Fig. 6. Immunoprecipitation f brain capillary proteins and P-gp from 
CHRC5 cells with MAb C219. Solubilized proteins from rat brain 
capillaries (CAP) and CHRC5 cells (CHRC5) were immunoprecipitated 
with MAb C219 as described in Materials and methods. Total (T), and 
the immunoprecipitated proteins (P) were separated by SDS-PAGE and 
Western blot analysis performed as described previously. 
two proteins (190 and 155 kDa) were strikingly different. 
First, in contrast with p190, p155 from BBB presented a 
high sensitivity towards heat treatment. P-gp from CHRC5 
cells was also sensitive to heat treatment [26]. Second, 
extraction of brain capillary proteins with a variety of 
detergents indicated that the two proteins detected by MAb 
C219 showed different patterns of solubilization. The de- 
tergents that solubilized efficiently p155 from brain capil- 
laries also solubilized P-gp from CHRC5 cells. P190 be- 
haved very differently since SDS was the only detergent 
that solubilized it. Urea (8 M) was the only other agent 
able to extract p190. Third, comparison of the hydrophobic 
properties by phase partitioning of the two proteins howed 
a strong difference. P155 partitioned in the detergent-rich 
phase and behaved like a membrane protein. In contrast, 
p190 was insoluble in Triton X-114. It is possible that 
p190 is a cytoskeleton associated protein since it was only 
solubilized by SDS and urea. The cytoskeleton is often 
experimentally defined as the insoluble residue remaining 
when cells are extracted with a non-ionic detergent [27]. 
Fourth, p155 and p190 reacted very differently to the 
N-deglycosylation treatment. P155 was more strongly af- 
fected in its migration pattern than p190. Fifth, lower 
concentration of the VQEALD peptide were required to 
abolish the binding of MAb C219 to p155 and to P-gp 
from CHRC5 cells than to p190. Finally, among brain 
capillary proteins, only p155 was immunoprecipitated by 
MAb C219. 
A cross-reactivity of MAb C219 to other membrane 
protein was recently reported. [19]. A protein of approx. 65 
kDa was immunodetected by Mab C219 in the drug resis- 
tant cell lines, P388/ADR and P388/VCR-600. This pro- 
tein seemed MDR-related and was called mini-P-glyco- 
protein. However, contrarily to P-gp, P-gPmini was not 
N-glycosylated neither phosphorylated at serine or threo- 
nine residues [19]. MAb C219 was also found to react 
immunohistochemically with striations in fast-twitch fibers 
in skeletal muscle [20]. 
A multidrug resistance associated membrane protein of 
190 kDa (MRP) gene is overexpressed in adriamycin 
resistant HL60 cells. However, the mdrl gene is not 
overexpressed in these cells and the level of P-gp is not 
detectable [28]. MRP, which binds ATP, presents a very 
small sequence homology with P-gp, since cross-reactivity 
of some antibodies against MRP is observed with P-gp 
[29]. However, the epitope recognized by MAb C219 is 
absent from the deduced amino acid sequence of MRP. 
These results uggest that p190 detected by MAb C219 in 
brain capillaries is not MRP. 
In the present study, two proteins (p155 and p190) were 
revealed by Western blot analysis of brain capillaries with 
MAb C219. The results suggest hat p155 is P-gp. How- 
ever, cross reactivity was observed between MAb C219 
and a glycoprotein of 190 kDa, probably unrelated to 
MDR. So, MAb C219, which is frequently used to demon- 
strate the presence of P-gp in tumor samples, also reacts 
with a distinct protein which could lead to false positive in 
the diagnosis of MDR in tumors. 
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